These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23817186)

  • 41. Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.
    Scott BB; McGeehan GM; Harrison RK
    Curr Protein Pept Sci; 2006 Jun; 7(3):241-54. PubMed ID: 16787263
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renin-angiotensin gene polymorphisms and neurohormonal inhibition.
    Pauly DF
    Heart Fail Clin; 2010 Jan; 6(1):25-6. PubMed ID: 19945057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Blockers of renin-angiotensin-aldosterone system in the treatment of arterial hypertension: classics versus the modern].
    Kanorskiĭ SG
    Kardiologiia; 2013; 53(10):89-95. PubMed ID: 24645559
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Direct renin inhibitors: ONTARGET for success?
    Pasha Y; Gusbeth-Tatomir P; Covic A; Goldsmith D
    Int Urol Nephrol; 2009; 41(2):341-55. PubMed ID: 19296235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [spACE, the last frontier? Renin inhibition in hypertension].
    Villa L
    G Ital Nefrol; 2008; 25(3):274. PubMed ID: 18473295
    [No Abstract]   [Full Text] [Related]  

  • 47. The blockade of renin-angiotensin-aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapy.
    Morishita Y; Kusano E
    Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):241-6. PubMed ID: 22023537
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The renin-angiotensin system in hypertension and in cardiovascular and renal diseases: highlights of the World Congress of Nephrology 2009]].
    Romet M
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H10-3. PubMed ID: 20129455
    [No Abstract]   [Full Text] [Related]  

  • 49. Novel molecular angiotensin converting enzyme and angiotensin receptor imaging techniques.
    Shirani J; Dilsizian V
    Curr Cardiol Rep; 2014 Apr; 16(4):466. PubMed ID: 24585108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The renin inhibitor aliskiren as novel treatment for cardiovascular disease.
    Saez AO; Philipp T; Nürnberger J
    Recent Pat Cardiovasc Drug Discov; 2006 Nov; 1(3):233-40. PubMed ID: 18221088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
    Pitt B
    Curr Heart Fail Rep; 2009 Jun; 6(2):112-6. PubMed ID: 19486595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors.
    Vistisen ST; Bodilsen J; Scheeren TWL; Simonsen U
    Eur J Anaesthesiol; 2020 Sep; 37(9):739-742. PubMed ID: 32769503
    [No Abstract]   [Full Text] [Related]  

  • 53. [Blocking the renin-angiotensin system in chronic kidney disease].
    Segura J
    Nefrologia; 2004; 24 Suppl(6):101-12, 187-235. PubMed ID: 15696901
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
    Powers B; Greene L; Balfe LM
    J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Various approaches to blockade of the renin-angiotensin system: persistent renin response.
    Brunner HR; Nussberger J; Waeber B
    J Hypertens Suppl; 1990 Dec; 8(7):S149-53. PubMed ID: 2095383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M; Ménard J
    Circulation; 2004 Jun; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.